Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Luteinizing Hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    233 result(s) found for: Luteinizing Hormone. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-002471-11 Sponsor Protocol Number: Leuprorelin-4002 Start Date*: 2022-08-08
    Sponsor Name:Takeda (China) International Trading Co., Ltd.
    Full Title: An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004860 10073186 Central precocious puberty LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2011-001193-26 Sponsor Protocol Number: C_30050_P3_02 Start Date*: 2011-12-21
    Sponsor Name:Acino Supply AG
    Full Title: An open label, one-arm, multiple dose study in patients with prostate cancer to demonstrate efficacy of a one month goserelin 3.6 mg implant in a two months treatment (2 application periods) and PK...
    Medical condition: Locally advanced, recurrent, or metastatic carcinoma of the prostate indicated for endocrine therapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10007462 Carcinoma prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003980-74 Sponsor Protocol Number: BAY1007626/15731 Start Date*: 2015-06-17
    Sponsor Name:Bayer AG
    Full Title: Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system releasing BAY 1007626,...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10010809 Contraception NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-003886-34 Sponsor Protocol Number: CFEM345ADE08 Start Date*: 2008-06-16
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Phase II study on letrozole in patients with advanced or recurrent hormone receptor positive endometrial cancer.
    Medical condition: endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004874-42 Sponsor Protocol Number: TRAFO001 Start Date*: 2009-02-06
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen M...
    Medical condition: The study examines the influence of pharmacogenetic markers on the efficacy and side effects in postmenopausal, steroid hormone positive breast cancer patients, who are treated with Letrozol. The p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002100-42 Sponsor Protocol Number: ARD-0301-003 Start Date*: 2005-08-24
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formu...
    Medical condition: advanced prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000328-85 Sponsor Protocol Number: FINNHT1 Start Date*: 2017-05-18
    Sponsor Name:Helsinki University Hospital, Obstetrics and Gynecology
    Full Title: Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life
    Medical condition: We will assess the effects of hormone therapy termination on endothelial function using biophysical (flow-mediated dilation, peripheral artery tonometry) and biochemical markers. We will compare th...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10027311 Menopause flushing LLT
    20.0 10041244 - Social circumstances 10076936 Impaired quality of life PT
    20.1 10038604 - Reproductive system and breast disorders 10027301 Menopausal hot flushes LLT
    20.1 10022891 - Investigations 10060858 Cardiovascular function test PT
    20.0 10041244 - Social circumstances 10027308 Menopause PT
    16.1 10038604 - Reproductive system and breast disorders 10027309 Menopause and related conditions HLGT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    20.0 10041244 - Social circumstances 10051775 Postmenopause PT
    20.0 10047065 - Vascular disorders 10048554 Endothelial dysfunction PT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000727-15 Sponsor Protocol Number: 9238IL/0048 Start Date*: 2004-12-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women with Hormone Receptor Positive A...
    Medical condition: Hormone receptor positive breast cancer with disease progression after prior non-steroidal aromatase inhibitor (AI) therapy
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-002122-67 Sponsor Protocol Number: 1211 Start Date*: 2013-12-05
    Sponsor Name:EORTC
    Full Title: Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.
    Medical condition: metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004796-11 Sponsor Protocol Number: CZOL446GDE24 Start Date*: 2007-08-14
    Sponsor Name:Klinikum Augsburg
    Full Title: An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast...
    Medical condition: Prevention of cancer treatment-related bone loss in postmenopausal women with resected stage I-IIIa hormone receptor positive breast cancer, who will receive letrozole as adjuvant therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001624-17 Sponsor Protocol Number: 210321 Start Date*: 2021-07-21
    Sponsor Name:Karolinska University Hospital
    Full Title: Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Prog...
    Medical condition: Climacteric symptoms
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001506-96 Sponsor Protocol Number: TCD12128 Start Date*: 2012-03-27
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A Phase I/II Study of Cabazitaxel Combined with Abiraterone Acetate and Prednisone in Patients with Metastatic Castrate-Resistant Prostate Cancer (CRPC) whose Disease has Progressed after Docetaxe...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001045-40 Sponsor Protocol Number: GEM-1805 Start Date*: 2020-03-03
    Sponsor Name:Grupo Español Multidisciplinar de Melanoma
    Full Title: Phase II, Open-Label Study of preliminary efficacy of Durvalumab (MEDI4736) in Combination with Cediranib in Patients with Metastatic Uveal Melanoma
    Medical condition: Metastatic uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000577-36 Sponsor Protocol Number: S60379 Start Date*: 2018-08-27
    Sponsor Name:University Hospitals Leuven
    Full Title: Durvalumab (MEDI4736) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study
    Medical condition: resectable, locally advanced squamous cell carcinoma of the oral cavity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002350-22 Sponsor Protocol Number: LR-201 Start Date*: 2020-01-14
    Sponsor Name:Chemo Research S.L.
    Full Title: Multi-center, phase 2, open-label, randomized clinical trial to evaluate the inhibition of ovulation of 3 dosing strengths of levonorgestrel (LNG) vaginal delivery system (VDS), releasing during 28...
    Medical condition: Women´s healthcare (Contraception, inhibition of ovulation)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10010808 Contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003888-71 Sponsor Protocol Number: CFEM345DDE09 Start Date*: 2005-07-20
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open phase III trial with Letrozole (Femara®) alone or in combination with Zoledronic acid (Zometa®) as extended adjuvant treatment of postmenopausal patients with primary breast cancer
    Medical condition: prevention of tumortherapy-induced bone loss
    Disease: Version SOC Term Classification Code Term Level
    8.0 10049470 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002662-40 Sponsor Protocol Number: AS.T.R.O.BC01-13 Start Date*: 2013-09-10
    Sponsor Name:AS.T.R.O.
    Full Title: PERtuzumab-trastuzumab plus lEetrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study
    Medical condition: Stage II-IIIA operable breast cancer, HER2 positive and hormone receptor-positive, previously untreated
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003087-59 Sponsor Protocol Number: EFC6193 Start Date*: 2006-11-29
    Sponsor Name:sanofi aventis recherche et developpement
    Full Title: A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone ...
    Medical condition: Hormone Refractory Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) BE (Completed) NL (Completed) SK (Completed) DK (Completed) SE (Completed) FI (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005742-39 Sponsor Protocol Number: ARD-0301-008 Start Date*: 2006-02-01
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formu...
    Medical condition: ADVANCED PROSTATE CANCER
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001648-64 Sponsor Protocol Number: No EP-24332T-A014 Start Date*: 2004-09-16
    Sponsor Name:ardana LTD
    Full Title: A Phase II multicentre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix 90 mg, long-acting f...
    Medical condition: advanced prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:06:18 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA